Module 9: Monitoring & Follow-Up
Lipid monitoring schedules, follow-up protocols, and response assessment.
Monitoring & Follow-Up
Generate a personalized monitoring schedule and goal assessment
Current Therapies (for goal assessment)
Monitoring Schedule
Guideline-based monitoring recommendations (Class I, Level B-NR)
| Test | Timing | Rationale |
|---|---|---|
| Lipid Monitoring | ||
| Lipid panel (nonfasting acceptable in most patients; fasting if known hypertriglyceridemia) | 4-12 weeks after initiation or dose change | Assess LDL cholesterol response to therapy. Expect >=30% reduction with moderate-intensity, >=50% with high-intensity statin. |
| Lipid panel (nonfasting acceptable in most patients; fasting if known hypertriglyceridemia) | Every 6-12 months once stable | Monitor adherence and sustained LDL cholesterol response. Annual minimum. |
| Lipoprotein(a) | Once in adult lifetime (at initial lipid assessment) | Lipoprotein(a) is genetically determined and stable over a lifetime. >=125 nmol/L is risk-enhancing. Measure at least once (Class 1, Level B-NR). |
| Safety Labs | ||
| Hepatic function panel (ALT) | Baseline prior to statin initiation | Baseline hepatic function. Routine monitoring no longer required unless symptoms develop. |
| Follow-Up | ||
| Clinical follow-up visit | 4-12 weeks after initiation, then every 6-12 months | Assess adherence, tolerability, lifestyle modification progress, and treatment goals. |
IMPORTANT: This software is clinical decision support (CDS) intended for use by licensed healthcare professionals under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act. It is not intended as a medical device. All recommendations are derived from the 2026 ACC/AHA Guideline on the Management of Dyslipidemia and must be independently verified by the treating clinician before any clinical action. AI-generated content (including extracted data and clinical notes) is produced by large language models and may contain errors, omissions, or hallucinations — clinician review is mandatory. Patient data entered into the calculator is processed entirely in the browser; AI features process data server-side under a signed HIPAA Business Associate Agreement with no data retention. AI-HEART Lab, its affiliates, and contributors assume no liability for clinical decisions made using this tool. By using this tool, you acknowledge these limitations and accept full responsibility for clinical decisions.